Our history…
Formed with the goal of providing carbohydrate-based solutions to the scientific community.
Sentinel Standards was organized as a business line of Sentinel Therapeutics, Inc in 2019 and comprises a core team of glyco-scientists led by Dr. Anthony Prudden. The assembled division has decades of cumulative experience where the team has worked on a spectrum of glyco-related projects. Whether using a chemical, enzymatic, or chemo-enzymatic synthetic strategy, the team is able to produce targets on a scale from milligrams to grams to support biophysical analysis or functional studies.
In its year of inception, the Sentinel team was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for the development of a library of isotopically labeled N-glycan standards. The result of the team’s effort was creation of the largest collection of structurally-defined, high-purity targets.
In addition to N-glycan synthesis, the team has experience in the following areas:
O-glycans
Human Milk Oligosaccharides
Glyco-epitopes
Glycopeptides
Heparin and Heparan Sulfate oligosaccharides
Glycan Biomarkers
Carbohydrate Modified dendrimers and nanoparticles
Microarray Screening